Shuxin Han | Molecular Mechanisms Signaling | Best Researcher Award

Published on by Cell Biologist

Dr. Shuxin Han | Molecular Mechanisms Signaling | Best Researcher Award

Dr. Shuxin Han | Xinjiang University | China

Dr. Shuxin Han is a distinguished molecular biologist and professor at Xinjiang University, widely recognized for his pioneering work in hepatobiliary and metabolic biology. With a research career spanning over two decades, Dr. Han has made major contributions to understanding how Kruppel-like factors, especially KLF15, regulate endobiotic and xenobiotic metabolism, impacting drug detoxification and metabolic disease mechanisms. He earned his Ph.D. from Kent State University and has held prestigious positions at Harvard Medical School and Case Western Reserve University. His groundbreaking studies have been published in high-impact journals like Nature Metabolism and Nature Communications, with several articles naming him as first or corresponding author. In addition to research, Dr. Han serves as a reviewer for top-tier journals in pharmacology, hepatology, and clinical science. He is also an academic leader, currently shaping the next generation of scientific talent and metabolic disease research in China.

Publication Profile: 

Scopus

Education:

Dr. Shuxin Han began his academic journey in Animal Sciences, earning a bachelor’s degree from Anhui Agricultural University (1994–1998). He advanced to a research assistant role at Peking University (1999–2000), where he deepened his scientific foundation. He then moved to the U.S. to pursue a Master’s in Biology at Temple University (2000–2003), followed by a Ph.D. in Molecular Biology from Kent State University (2004–2009), focusing on metabolic biology and gene regulation. This progression from general animal sciences to highly specialized molecular biology reflects a systematic and deep commitment to biomedical research. His strong academic preparation laid the foundation for a research career investigating how transcriptional regulators impact health and disease. Dr. Han’s training spans world-class institutions across both China and the United States, equipping him with diverse scientific perspectives and techniques.

Experience:

Dr. Shuxin Han has accumulated rich research and academic experience over nearly 30 years. His early career included a pivotal research assistant role at Peking University, followed by advanced training in biology and molecular biology at Temple and Kent State Universities. He completed prestigious postdoctoral training at Harvard Medical School (2009–2012) and Case Western Reserve University (2012–2015), where he later became a Senior Research Associate (2015–2019). He returned to China in 2019 as a Researcher at the University of Science and Technology of China First Affiliated Hospital, simultaneously engaging in academic duties at the university until 2023. Currently, he serves as a Professor and Academic Leader at Xinjiang University. Throughout his career, Dr. Han has built strong international collaborations, led research groups, and guided innovative projects in metabolic biology, demonstrating his leadership, research excellence, and academic mentorship capabilities.

Research Focus:

Dr. Shuxin Han’s research centers on the molecular regulation of metabolism, particularly focusing on the hepatobiliary and gastrointestinal systems. His work has elucidated the critical role of the Kruppel-like factor (KLF) family, especially KLF15, in controlling endobiotic and xenobiotic metabolism (EXM). These pathways govern how the body metabolizes both internal compounds and external substances like drugs. Dr. Han’s studies have shown that KLF15 acts as a master regulator, influencing drug resistance, liver injury, and metabolic homeostasis. His discoveries offer new insight into personalized medicine and treatment for metabolic disorders and drug-related toxicities. With numerous first-author and corresponding-author publications in journals such as Nature Metabolism, Nature Communications, and Drug Metabolism and Disposition, his work has significantly impacted both fundamental science and clinical applications. He is also active in peer-reviewing for top-tier journals and is recognized for his leadership in translational research.

Publications Top Notes:

  1. Unveiling KLF15 as the Key Regulator of Cyclosporine A Metabolism and Adverse Effects – Drug Metabolism and Disposition, 2025

  2. Distribution and Functional Significance of KLF15 in Mouse Cerebellum – Molecular Brain, 2025

  3. Personalized Statin Therapy: Targeting Metabolic Processes – Heliyon, 2025

  4. Current Status and New Directions for Hepatocellular Carcinoma Diagnosis – Liver Research, 2024

  5. KLF15-Cyp3a11 Axis Regulates Rifampicin-Induced Liver Injury – Drug Metabolism and Disposition, 2024

  6. Advancing Drug Delivery and Bioengineering in Liver Research – Bioengineering and Translational Medicine, 2024

  7. Advances in IL-7 Research on Tumor Therapy – Pharmaceuticals, 2024 (Co-author)

  8. Pathogenic Mechanisms in Alcoholic Liver Disease – Journal of Translational Medicine, 2023

  9. Beta-Hydroxybutyrate Effects on iPSC-Derived Cardiac Myocytes – Biomolecules, 2022

  10. Interactions Between Intestinal Flora and Bile Acids – International Journal of Molecular Sciences, 2022 (Corresponding author)

Conclusion:

In conclusion, Dr. Shuxin Han is a highly deserving candidate for the Best Researcher Award. His pioneering work on KLF15 and metabolic regulation has reshaped fundamental understanding in the field of hepatobiliary biology and pharmacology. His academic background, research productivity, international experience, and editorial service all reflect a well-rounded and impactful scientist. While there is room to increase clinical translation and international engagement, the depth, originality, and consistency of his research make him a strong contender for this recognition. Honoring Dr. Han with this award would acknowledge a career dedicated to scientific advancement with substantial implications for human health and drug therapy.

Amr Hanbali | Therapeutic use of Cellular therapy in cancer treatment | Best Researcher Award

Published on by Cell Biologist

Assoc. Prof. Dr. Amr Hanbali | Therapeutic use of Cellular therapy in cancer treatment | Best Researcher Award

Assoc. Prof. Dr. Amr Hanbali | King Faisal Specialist Hospital & Research Center | Saudi Arabia

Dr. Amr AlHanbali is a dual-certified Hematology and Oncology consultant with over 18 years of experience in malignant and benign hematological conditions. Based at King Faisal Specialist Hospital & Research Center in Riyadh, Saudi Arabia, he specializes in hematologic malignancies and stem cell transplantation. Dr. AlHanbali previously served as a senior staff physician and Associate Fellowship Program Director at Henry Ford Health System in Detroit, Michigan. Recognized for his academic involvement, he holds teaching appointments at Wayne State University and Alfaisal University. Known for his dedication to clinical mentorship, he has trained numerous medical students, residents, and fellows. He is actively involved in research and is a member of several prestigious medical organizations including the American Society of Hematology and American Society of Clinical Oncology. With expertise ranging from bone marrow procedures to managing complex hematologic disorders, Dr. AlHanbali is a respected leader in the field of hematology and stem cell transplantation.

Publication Profile:

Scopus

Strengths for the Award:

  1. Extensive Research Contribution

    • Over 17 peer-reviewed publications, including impactful case reports, national guidelines, and original research in hematology, oncology, and stem cell transplantation.

    • Active contributor to national guidelines on multiple myeloma, reflecting leadership in shaping national healthcare standards in KSA.

  2. Dual Academic and Clinical Roles

    • Combines academic excellence (as faculty at Wayne State University and Alfaisal University) with hands-on clinical expertise at a premier institution (King Faisal Specialist Hospital & Research Center).

  3. Innovative Focus in Hematology and Transplantation

    • Research into underexplored areas such as hepatitis B reactivation post-rituximab, genetic donor match outcomes, and therapies for AL amyloidosis.

  4. International Exposure and Leadership

    • Experience across the U.S. and Saudi Arabia, influencing programs in both systems.

    • Played a key role in training and selecting future hematology-oncology fellows in the U.S.

  5. Mentorship and Capacity Building

    • Mentored numerous trainees, enhancing research culture among younger clinicians.

Areas for Improvement:

  1. Higher Impact Publications Needed

    • While the volume and variety of research are commendable, more publications in top-tier journals (NEJM, Lancet, Blood, JCO) could boost citation impact and visibility.

  2. Research Grants and Collaborative Trials

    • Pursuing multicenter studies, international collaborations, or industry-sponsored clinical trials would further elevate his profile and expand research funding sources.

  3. Technological Innovation/Patents

    • Exploring biotech innovation, AI in diagnostics, or cellular therapy patents could position him among the top medical innovators.

Education:

Dr. Amr AlHanbali completed his Bachelor of Medicine and Surgery from the University of Jordan in 1999. He pursued medical training in the United States, starting with an internal medicine residency (2001–2004) at Henry Ford Health System, Detroit. He continued his specialization with a fellowship in Hematology and Oncology (2004–2007) at the same institution. During his training, he also undertook elective rotations in Pediatric Cardiology and Gastroenterology at the University of Texas Medical Branch, Galveston, further enriching his academic exposure. He is certified by the American Board of Internal Medicine in Internal Medicine (2004), Hematology (2007), and Oncology (2007). Dr. AlHanbali holds academic titles as a Clinical Assistant Professor at Wayne State University, Detroit, and Adjunct Associate Professor at Alfaisal University, Riyadh. His educational background reflects a strong foundation in internal medicine, with a deep focus on hematology and oncology, further supported by teaching and research excellence.

Experience:

Dr. AlHanbali’s clinical career spans over 18 years, currently serving as Hematology and Stem Cell Transplant Consultant at King Faisal Specialist Hospital & Research Center in Riyadh since 2013. Prior to this, he held multiple leadership roles at Henry Ford Health System, Detroit, including Senior Staff Physician and Associate Fellowship Program Director (2007–2013). His medical expertise covers the diagnosis and treatment of a wide range of hematologic malignancies such as leukemia, lymphoma, multiple myeloma, and myeloproliferative disorders. Dr. AlHanbali also has extensive experience in stem cell transplantation, intrathecal chemotherapy, and bone marrow biopsy. He has been instrumental in resident selection and curriculum development for fellowship programs in hematology and oncology. His work bridges clinical excellence with academic mentorship, guiding numerous trainees and junior physicians. In addition to patient care, he is involved in clinical guideline development and research, particularly in the field of multiple myeloma and transplant outcomes.

Research Focus:

Dr. Amr AlHanbali’s research is centered on hematologic malignancies, particularly multiple myeloma, lymphoma, leukemia, and stem cell transplantation. His work explores novel therapeutic approaches, transplant outcomes, disease progression, and treatment-related complications. He has contributed significantly to research on hepatitis B reactivation, chemotherapy-induced toxicities, and the protective role of comorbidities like diabetes in cancer metastasis. As an active member of the Saudi Myeloma Working Group, he has co-authored national guidelines for both newly diagnosed and relapsed/refractory multiple myeloma. His studies also examine health disparities in cancer care, including outcomes among African American populations and the impact of familial genetics in donor matches. With over a dozen peer-reviewed publications and case reports in high-impact journals, Dr. AlHanbali continues to push forward understanding in clinical hematology and oncology. He combines bedside insights with academic rigor to shape evidence-based practice and improve treatment outcomes in cancer and transplant medicine.

Publications Top Notes:

  1.  Mediastinal Hematoma With SVC Syndrome From A Central Venous Catheter Insertion – CHEST, 2003

  2.  Diabetes Has Protective Effect Against Metastasis in Non-Small Cell Lung Cancer – Arch Intern Med, 2007

  3.  Delayed Hepatitis B Viral Replication Post-Rituximab & Fludarabine in Waldenstrom Macroglobulinemia – Am J Hematol, 2007

  4.  Acute Pancreatitis Induced by Adult Precursor B-cell ALL – South Med J, 2007

  5.  Hypersensitivity Reaction of Mylotarg with Platelet Transfusion – Am J Health Syst Pharm, 2007

  6.  Incidence of Hepatitis B Reactivation after Rituximab Therapy – Am J Hematol, 2009

  7. Outcomes After Auto-SCT in African Americans with Multiple Myeloma – Bone Marrow Transplant, 2009

  8.  HER-2 Status May Change in Recurrent Breast Cancer – Cancer Research, 2009

  9.  Compartment Syndrome as Presentation of Chronic Myelogenous Leukemia – J Gen Intern Med, 2010

  10.  Use of Insulin and its Effect on Survival in NSCLC – J Clin Oncol, 2009

Conclusion:

Dr. Amr AlHanbali demonstrates a stellar blend of clinical expertise, research productivity, academic mentorship, and leadership in hematology and oncology. His research contributions have practical implications in areas such as multiple myeloma, leukemia, transplant immunology, and chemotherapy safety.

He is highly deserving of recognition and stands out as a top contender for a Best Researcher Award, particularly in the categories of clinical research excellence, translational hematology, and medical education integration with research.

Chun Yan | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Dr. Chun Yan | Stem Cell Research | Best Researcher Award

Dr. Chun Yan, Department of Thoracic Surgery, Zhongshan Hospital of Xiamen University, China

Dr. Yan Chun is an Attending Physician at the School of Medicine/Zhongshan Hospital, Xiamen University. With a solid foundation in clinical medicine and surgery, Dr. Chun brings over a decade of experience in thoracic oncology and AI-driven medical research. After earning a Bachelor’s degree from Fujian Medical University, he pursued his Master’s in Surgery at Shanghai Jiao Tong University. Since 2018, Dr. Chun has contributed significantly to clinical practice, medical innovation, and academic research. His current focus includes AI-assisted diagnosis, radiogenomics, and the biomechanics of thoracic surgery. A recognized member of the Minimally Invasive Thoracic Oncology Committee under the Fujian Primary Health Association, he has received multiple accolades for his pioneering work in esophageal cancer therapy. Dr. Chun’s commitment to precision medicine and integration of AI in healthcare highlights his suitability for prestigious research honors and positions him as a leader in translational medical research in China.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Strong Academic Foundation: Dr. Yan Chun holds a Master’s degree in Surgery from Shanghai Jiao Tong University and a Bachelor’s degree in Clinical Medicine, ensuring a robust foundation in both research and clinical practice.

  2. Innovative Research: He leads and participates in cutting-edge projects that integrate AI, radiogenomics, and biomechanical modeling, reflecting a multidisciplinary and forward-thinking approach.

  3. Recognized Excellence: His work has been honored with regional innovation and scientific progress awards, demonstrating tangible contributions to thoracic oncology.

  4. Clinical Expertise: With 7+ years of medical experience, including as an attending physician, he bridges practical medicine with impactful research.

  5. Leadership Role: Serving on a professional committee in minimally invasive thoracic oncology highlights his thought leadership within his specialty.

🧠 Areas for Improvement:

  1. Expanded Publication Record: While impactful, Dr. Chun’s publication portfolio would benefit from a broader presence in international, high-impact journals to boost academic visibility.

  2. International Collaboration: Engaging in cross-border research partnerships could enhance both innovation scope and influence.

  3. Grant Scale: Existing grants are modest in size. Applying for national-level or larger competitive grants could support more ambitious projects.

  4. Mentorship and Training: Documenting roles in mentoring junior researchers or medical students would strengthen his academic leadership profile.

🎓 Education:

Dr. Yan Chun’s academic journey began with a Bachelor of Clinical Medicine (MBBS) from Fujian Medical University (2010–2015), where he gained fundamental clinical knowledge and medical training. He then advanced his specialization in surgery by completing a Master of Surgery (MS) at Shanghai Jiao Tong University (2015–2018), one of China’s top medical institutions. His education emphasized evidence-based clinical practice, surgical skills, and research methodology. During his postgraduate studies, he was actively involved in academic projects, laying a strong foundation for his later research in thoracic oncology and artificial intelligence in medicine. This robust educational background equips him with interdisciplinary expertise, bridging clinical medicine, surgical techniques, and research innovation—especially in radiogenomics and perioperative therapies for esophageal cancer. His training reflects both academic rigor and a forward-looking approach to integrating emerging technologies with healthcare delivery, making him well-prepared to drive impactful research initiatives.

💼 Experience:

Dr. Yan Chun has held progressive roles at Zhongshan Hospital, Xiamen University since 2018. Starting as a Physician (2018–2023), he delivered comprehensive clinical care while engaging in translational research projects. Since July 2023, he has been serving as an Attending Physician, contributing to surgical excellence and AI-assisted diagnostic strategies in thoracic oncology. His hands-on clinical experience is complemented by leadership in grant-funded research, particularly in predictive modeling and biomechanics. Dr. Chun’s involvement in multi-disciplinary teams, collaborations with AI scientists, and contributions to surgical innovation have advanced the care standards in thoracic surgery. He has also actively contributed to institutional and provincial-level scientific programs, showcasing his capability in both practical medicine and medical research. His work stands at the intersection of clinical practice and innovation, and he remains committed to improving outcomes for patients with complex thoracic conditions through precision diagnostics and minimally invasive techniques.

🏅 Awards and Honors:

Dr. Yan Chun has received multiple accolades recognizing his innovative contributions to thoracic oncology and surgical AI. His project, “AI-Assisted Precision Perioperative Individualized Therapy for Esophageal Cancer”, was selected as one of the Top Ten Innovations of the Year by the Xiamen Hospital Association, highlighting its impact on personalized medicine. Another landmark project, “Precision Diagnosis and Treatment Paradigm for Esophageal Squamous Cell Carcinoma Driven by AI and Multi-Omics Integration”, earned him the Third Prize for Scientific and Technological Progress from the Fujian Anti-Cancer Association, underscoring his leadership in advanced cancer care. His awards reflect not only clinical innovation but also excellence in multi-disciplinary research. These honors are a testament to his ability to bridge clinical needs with technological advancements, demonstrating vision, technical skill, and translational impact. They position him as a high-impact researcher contributing meaningfully to China’s evolving healthcare landscape.

🔬 Research Focus:

Dr. Yan Chun’s research is primarily centered on the integration of artificial intelligence, radiogenomics, and thoracic oncology. He leads a government-funded project investigating deep learning-based predictive models for lymph node metastasis and prognosis in esophageal cancer, leveraging imaging-genomics to improve pre- and post-operative decision-making. He also contributed to biomechanical analysis of the NUSS procedure for pectus excavatum, applying finite element modeling to improve surgical outcomes. His work merges clinical data science, image processing, and genomics, aiming to build personalized treatment pathways and enhance minimally invasive approaches. Dr. Chun’s interdisciplinary approach reflects a deep understanding of both computational technologies and real-world clinical challenges. His ambition is to develop AI-powered platforms that augment oncological diagnostics and optimize surgical interventions. Through a combination of hands-on experience and research rigor, he is at the forefront of precision medicine in thoracic surgery, striving for innovation that is both data-driven and patient-centered.

📚 Publications Top Notes:

📖 Association between per- and polyfluoroalkyl substances exposure and prevalence of chronic obstructive pulmonary disease: The mediating role of serum albumin – Science of the Total Environment, 2024 🌱🫁

🧾 Conclusion:

Dr. Yan Chun demonstrates exceptional promise and maturity as a clinical researcher whose work lies at the confluence of AI, precision medicine, and thoracic surgery. His contributions to the diagnosis and treatment of esophageal cancer through radiogenomic modeling and minimally invasive techniques are both innovative and clinically meaningful. Backed by professional recognition and a strong clinical research ethic, Dr. Chun is a worthy candidate for the Best Researcher Award. With expanded international presence and high-impact publications, he is poised to become a leading figure in the global thoracic oncology research community.

Mohammad reza Atashzar | Cancer stem cell | Best Researcher Award

Published on by Cell Biologist

Dr. Mohammad reza Atashzar | Cancer stem cell | Best Researcher Award

Dr. Mohammad reza Atashzar, Dep of immunology, Fasa university of medical sciences ( FUMS ), Iran

Dr. Mohammad Reza Atashzar is an Assistant Professor in the Department of Immunology at Fasa University of Medical Sciences (FUMS), Iran. With an enduring passion for tumor immunology, stem cells, vaccine design, and immunotherapy, he has made significant contributions through both basic and translational research. Dr. Atashzar earned his PhD in Immunology from Shahid Beheshti University of Medical Sciences and has since engaged in teaching, mentoring, and publishing extensively in high-impact journals such as The Lancet Oncology, Frontiers in Immunology, and Current Molecular Medicine. His innovative research spans exosome-based therapy, cancer biomarkers, cytokine profiling, and radiogenomics. Dr. Atashzar has also contributed to international collaborations across Germany, Finland, and the UK, showcasing a global outlook in biomedical science. An awardee of the KAI 2022 International Travel Grant and recognized as the Top Researcher at FUMS in 2021, he remains deeply committed to advancing immunological sciences for clinical and therapeutic benefit.

Publication Profile: 

Orcid

Google Scholar

✅ Strengths for the Award:

  1. Extensive Research Contributions
    Dr. Atashzar has authored numerous peer-reviewed publications in reputable journals including The Lancet Oncology, Frontiers in Immunology, Current Molecular Medicine, and Computers in Biology and Medicine. His work spans critical fields like cancer immunology, exosome therapy, stem cell immunomodulation, and vaccine research.

  2. High-Impact Publications
    Several of his papers have significant citation counts—556 for Frontiers in Immunology, 284 for Journal of Cellular Physiology, and 207 for The Lancet Oncology, reflecting strong influence and relevance in the scientific community.

  3. International Recognition and Collaborations
    He has participated in international conferences (UK, China, Korea, Denmark, Spain, Italy) and collaborated with global institutions such as the University of Helsinki, University of Kiel, and GBD Collaborators, demonstrating a global research footprint.

  4. Innovation and Patents
    He has contributed to translational science through a published book on immunopharmacology and a pending patent for a microbiology loop sterilizer device, showing practical application of his research.

  5. Awards and Editorial Involvement
    Recognized with the International Travel Award (KAI 2022) and Top Researcher of FUMS (2021), and serving on editorial boards of scientific journals—further affirming his active role in academic development and peer review.

  6. Interdisciplinary Research Scope
    His research merges clinical immunology, oncology, AI-based prognostic tools, and cellular therapy, making his work not only innovative but also future-oriented.

⚠️ Areas for Improvement:

  1. Increase in First or Senior Author Publications
    While his contributions are numerous, strengthening his authorship role in key studies would amplify his recognition as a principal investigator.

  2. Patent Commercialization & Technology Transfer
    Moving from patent design to real-world implementation or licensing could significantly raise the translational value of his research.

  3. Higher Grant Involvement
    More participation in national/international grant-funded programs or consortiums would enhance the scale and visibility of his research.

  4. Focused Research Niche
    Narrowing focus slightly (e.g., prioritizing tumor immunology or exosome-based therapies) could help build a globally recognized brand in a specialized field.

🎓 Education:

Dr. Atashzar completed his undergraduate and master’s studies in Immunology at Shiraz University of Medical Sciences (SUMS), Shiraz, Iran. Building on his foundational expertise, he pursued his PhD in Immunology at Shahid Beheshti University of Medical Sciences, Tehran. His doctoral thesis—“Investigation of the Effects of B16F10 Derived Exosomes Enriched with miRNA-211 in Induction of Antitumor Response in the Mouse Model of Melanoma”—reflected his early interest in cancer immunotherapy and translational research. Throughout his academic journey, Dr. Atashzar displayed a strong inclination toward exploring novel immune pathways and cell-based therapies. His formal education has laid a robust foundation for his ongoing work in immunological sciences, particularly in relation to tumor microenvironment, cytokine profiling, exosomes, and vaccine innovation. He has also undertaken continuous learning through collaborations and international scientific conferences, allowing him to integrate cutting-edge methodologies into his research and teaching repertoire.

🧪 Professional Experience:

Dr. Mohammad Reza Atashzar currently serves as an Assistant Professor of Immunology at Fasa University of Medical Sciences, with additional teaching responsibilities at Larestan University of Medical Sciences. He has accumulated over a decade of experience in academic instruction and biomedical research. His research portfolio includes multiple funded projects, notably in cancer immunology, cytokine regulation, diabetes-related immune responses, and exosome-based therapeutics. Dr. Atashzar has worked closely with international teams in Germany, Finland, and the UK, facilitating interdisciplinary approaches and innovations in clinical immunology. He is an editorial board member for reputed journals such as The International Journal of Neuroscience and Journal of International Medical Research. In parallel, he actively contributes to conference presentations worldwide, covering topics from cancer stem cells to immune biomarkers. His hands-on laboratory experience, combined with a global research network, enables him to lead and mentor in advanced areas like CAR-T cell therapy and personalized immunotherapy.

🧬 Research Focus:

Dr. Atashzar’s research is centered on tumor immunology, exosome-based therapies, cancer stem cells, CAR-T cell technology, cytokine profiling, and immunopharmacology. He has a keen interest in how immune cells—particularly T cells, NK cells, and regulatory B cells—can be harnessed for cancer therapy. His notable projects have explored the immunomodulatory effects of miRNA-enriched exosomes, the role of TLR4 polymorphisms in diabetes, and cytokine alterations in addiction and radiation-exposed individuals. He is also pioneering in translational research areas such as vaccine design, radiogenomics, and bio-immune device development. Dr. Atashzar integrates bioinformatics and machine learning for predictive modeling, evident in his contributions to COVID-19 prognostic modeling using CT radiomics. His work is driven by the goal of personalized immunotherapy and the identification of novel biomarkers for cancer progression and immune regulation. Through interdisciplinary collaborations, he aims to bridge the gap between immunological research and clinical application.

📚 Publications Top Notes:

  1. 🧬 Cancer stem cells: A review from origin to therapeutic implications – Journal of Cellular Physiology

  2. 🧪 Tumor‐Derived Exosomes Enriched by miRNA‐211a Promote Antitumor Immune Response in B16F10 Tumor‐Bearing Mice – APMIS

  3. 🔬 The effects of tumor-derived exosomes enriched with miRNA-211a on B16F10 cells – Contemporary Oncology

  4. 💉 The effects of type 2 diabetes mellitus on organ metabolism and the immune system – Frontiers in Immunology

  5. 🧠 Pyrin and hematopoietic interferon-inducible nuclear protein domain proteins: innate immune sensors for cytosolic and nuclear DNA – Critical Reviews in Immunology

  6. 🧪 Reduced levels of T-helper 17-associated cytokines in serum of breast cancer patients – Central European Journal of Immunology

  7. 🧫 The Role of IL‐6, IL‐10 and CRP in Gastrointestinal Cancers – Cell Biology International

  8. 🌍 The global burden of adolescent and young adult cancer in 2019 – The Lancet Oncology

  9. 🖥️ COVID-19 prognostic modeling using CT radiomic features and ML algorithms – Computers in Biology and Medicine

  10. 🌡️ Mesenchymal stromal cells in bone marrow niche of multiple myeloma – Cancer Cell International

📌 Conclusion:

Dr. Mohammad Reza Atashzar is highly suitable for the Best Researcher Award. His body of work reflects a deep commitment to scientific advancement in cancer immunology, immunotherapy, and bio-innovation. He combines strong academic output with international engagement, cross-disciplinary impact, and teaching contributions. With growing influence in both research and translational domains, Dr. Atashzar is poised to further elevate biomedical research in Iran and globally.

ALINE TAKEJIMA | Tissue engineering | Women Researcher Award

Published on by Cell Biologist

Dr. ALINE TAKEJIMA | tissue engineering | Women Researcher Award

Dr. ALINE TAKEJIMA, pontificia universidade catolica do parana, Brazil

Dr. Aline Luri Takejima is a physician-scientist from Brazil, specializing in regenerative medicine and wound healing. She holds an MD and a PhD in Health Sciences from the Pontifical Catholic University of Paraná (PUCPR), where she currently conducts postdoctoral research. With a focus on biological therapies involving the amniotic membrane, Wharton’s jelly, and mononuclear stem cells, Dr. Takejima has published in multiple high-impact scientific journals. Her research aims to develop novel regenerative strategies to treat complex wounds and enhance tissue repair. As an active member of PUCPR’s Wound Healing Research Group and the Brazilian Society of Plastic Surgery, she combines scientific rigor with clinical insight to bridge bench-to-bedside innovation. Her academic contributions are guided by a translational approach, offering promising avenues for future clinical applications in tissue engineering.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. Focused Research Excellence:
    Dr. Takejima’s work on biological scaffolds and stem cells in wound healing is both innovative and clinically relevant. Her studies using amniotic membrane, Wharton’s jelly, and bone marrow mononuclear cells show promising regenerative outcomes in preclinical models.

  2. Research Productivity:
    With 9 peer-reviewed journal articles in high-quality platforms (e.g., Biomedicines, Tissue Barriers, Annals of Biomedical Engineering), she demonstrates consistent academic output in her field.

  3. Translational Impact:
    Her research bridges basic science and clinical practice, aiming to provide regenerative solutions for patients with chronic wounds and cardiac damage.

  4. Collaborative Engagement:
    Active participation in a multidisciplinary wound healing research group, contributing to cross-functional scientific advancements.

  5. Recognition Potential:
    As a young, emerging woman researcher in biomedical sciences, she stands as a role model for future female scientists in Latin America and beyond.

🔧 Areas for Improvement:

  1. Intellectual Property & Innovation:
    No patents filed yet; transitioning her research into patentable therapies or commercial applications would increase its societal and economic impact.

  2. Leadership Roles:
    While active in research, taking on editorial or scientific leadership positions would enhance her academic visibility and influence.

  3. Internationalization:
    She would benefit from developing international collaborations or fellowships to diversify her research scope and increase global reach.

  4. Industry Engagement:
    Engaging in consultancy or biotech partnerships can further the translational impact of her regenerative strategies.

🎓 Education:

Dr. Takejima’s educational journey began with a Doctor of Medicine (MD) degree from the Pontifical Catholic University of Paraná (PUCPR), Brazil. Her passion for research led her to pursue a Doctorate (PhD) in Health Sciences/Medicine, also at PUCPR. Her doctoral thesis focused on the use of biologically active materials such as the amniotic membrane and stem cells to enhance wound healing. Throughout her academic training, she demonstrated a strong commitment to translational medicine by integrating basic science with clinical practice. During her PhD, she engaged in experimental models involving stem cell therapy and tissue engineering, which laid the groundwork for her current postdoctoral research. Her educational path reflects both depth and specialization in the biomedical sciences, particularly in regenerative medicine and cellular therapies.

💼 Experience:

Dr. Aline Takejima has over a decade of experience in medical and scientific fields, balancing her role as a physician with that of a postdoctoral researcher. Her clinical background informs her research, particularly in areas of wound healing and regenerative medicine. At PUCPR, she contributes to the Wound Healing Research Group, where she is involved in designing and conducting animal model studies to test the effects of biomaterials and stem cells. Her multidisciplinary research integrates immunology, histopathology, and molecular biology. With nine peer-reviewed publications and participation in collaborative research, she has become a respected contributor to the field. Though early in her research career, her trajectory shows a steady rise, marked by evidence-based outcomes and a commitment to innovation. Her goal is to bridge clinical challenges with regenerative solutions that can be implemented in real-world medical practice.

🔬 Research Focus:

Dr. Takejima’s research focuses on regenerative strategies for wound healing, utilizing biomaterials and stem cells. Her work primarily explores the application of amniotic membrane, Wharton’s jelly, and bone marrow-derived mononuclear stem cells in treating complex or chronic skin wounds. Using experimental models in rats and rabbits, she evaluates histological recovery, inflammation modulation, and tissue regeneration. A significant aspect of her research is understanding how these materials promote healing through paracrine effects rather than direct integration, offering a safer and scalable pathway to clinical application. Additionally, her work extends to cardiac and tracheal tissue repair, emphasizing the versatility of these regenerative approaches. The translational nature of her research bridges laboratory discoveries with potential bedside applications, positioning her at the forefront of cellular therapy and biomaterials science.

📚 Publications Top Notes:

  1. 🧠 Wharton’s Jelly Bioscaffolds Improve Cardiac Repair with Bone Marrow Mononuclear Stem Cells in Rats – Journal of Functional Biomaterials, 2025

  2. 🧫 The effects of decellularized amniotic membrane and Wharton’s jelly on the healing of experimental skin wounds in rats – Tissue Barriers, 2025

  3. ❤️ Bone-marrow mononuclear cells and acellular human amniotic membrane improve global cardiac function… – Anais da Academia Brasileira de Ciências, 2024

  4. 🫁 Tracheal regeneration with acellular human amniotic membrane and 15d-PGJ2 nanoparticles in rabbits – Anais da Academia Brasileira de Ciências, 2023

  5. 🧬 Acellular Biomaterials + Autologous Stem Cells Improve Wound Healing via Paracrine Effects – Biomedicines, 2023

  6. 💉 Decellularized Amniotic Membrane Solubilized with Hyaluronic Acid in Wound Healing – Annals of Biomedical Engineering, 2022

  7. 🧪 Role of Mononuclear Stem Cells and Decellularized Amniotic Membrane in Skin Wounds – Tissue Barriers, 2022

  8. 🏥 Trauma hepático: epidemiologia de cinco anos… – Revista do Colégio Brasileiro de Cirurgiões, 2008

🧾 Conclusion:

Dr. Aline Luri Takejima is an outstanding candidate for the Women Researcher Award. Her academic profile demonstrates a strong foundation in regenerative medicine with significant contributions to wound healing research. Her commitment to applying biological therapies in clinical contexts shows both depth and innovation. As a woman scientist in a competitive field, she exemplifies leadership, dedication, and potential. With further growth in global engagement and innovation strategy, Dr. Takejima is poised to become a future leader in regenerative biomedical research.

Hongliang Xin | Tissue Engineering Regeneration | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Hongliang Xin | Tissue Engineering Regeneration | Best Researcher Award

Prof. Dr. Hongliang Xin, Nanjing Medical University, China

Professor Hongliang Xin is a distinguished pharmaceutical scientist at Nanjing Medical University, China. After earning his PhD from Fudan University in 2011, he joined Nanjing Medical University and rapidly rose through academic ranks, becoming a full professor by 2020. His international experience includes a research fellowship at North Carolina State University (2015–2016), enriching his global academic outlook. Professor Xin has made significant contributions in drug delivery, particularly for brain disorders and cancer. His work on biomimetic nanoparticles and dual-targeting systems has been widely recognized, with several of his publications cited hundreds of times. He is a recipient of the Jiangsu Outstanding Research Award and has contributed to translational science through interdisciplinary collaboration. Committed to innovation in intelligent drug delivery, Professor Xin continues to push boundaries in nanomedicine. His dedication and impactful research make him a strong candidate for the Best Researcher Award.

Publication Profile: 

Google Scholar

✅ Strengths for the Award:

  1. Innovative Research in Drug Delivery
    Prof. Xin has led pioneering work in cellular biomimetic drug delivery systems and brain-targeted therapies, particularly utilizing Angiopep-conjugated and ROS-responsive nanoparticles. His research shows deep innovation in crossing the blood-brain barrier — a major challenge in neuroscience and oncology.

  2. Strong Publication Record
    He has authored multiple high-impact publications in top-tier journals such as Biomaterials, ACS Nano, and Advanced Materials. Several of these works have citations exceeding 300–400, indicating significant influence in the scientific community.

  3. International Research Exposure
    His experience as a visiting scholar at North Carolina State University reflects a global approach to science, enhancing both the breadth and depth of his research collaborations.

  4. Consistent Career Growth
    From lecturer to professor within a decade, Prof. Xin’s steady academic rise reflects both merit and dedication.

  5. Recognition and Awards
    Recipient of the Jiangsu Outstanding Research Award, validating his contributions at the provincial and national level.

⚙️ Areas for Improvement:

  1. Clinical Translation
    While preclinical research is robust, moving towards clinical trials or commercial partnerships would greatly strengthen the translational impact of his work.

  2. Leadership in International Consortia
    Increased participation or leadership in global research initiatives, conferences, or consortia could further elevate his visibility and impact internationally.

  3. Cross-Disciplinary Outreach
    Expanding collaborations into neuropsychology, regenerative medicine, or pharmaceutical industry applications could broaden the application of his delivery systems.

🎓 Education:

Hongliang Xin completed his doctoral studies in Pharmacy at Fudan University in 2011, one of China’s most prestigious universities. His academic journey was grounded in pharmaceutical sciences, focusing on drug delivery systems and nanotechnology-based therapies. During his PhD, he laid the foundation for his future research in targeted therapy and biomimetic materials. Post-PhD, he expanded his academic training internationally as a visiting scholar at North Carolina State University in the United States (2015–2016). This exposure to global research trends and interdisciplinary approaches further honed his expertise. The integration of chemical engineering, pharmacology, and nanotechnology into his educational training has allowed him to develop innovative and effective therapeutic strategies for brain-targeted drug delivery. His education has not only equipped him with strong technical skills but also with a visionary approach to translational medicine.

🧪 Experience:

Dr. Hongliang Xin began his academic career as a lecturer at Nanjing Medical University’s School of Pharmacy in 2011. He was promoted to Associate Professor in 2015 and became a Full Professor in 2020. Over the years, he has built a robust research program in nanomedicine and drug delivery, leading multiple funded projects and mentoring graduate students. His one-year tenure as a visiting scholar at North Carolina State University provided him international collaborative opportunities, boosting his cross-disciplinary competence. Professor Xin has published extensively in high-impact journals such as Biomaterials, ACS Nano, and Advanced Materials. He is also a recognized leader in translational drug delivery platforms, specifically for brain diseases and cancer. His extensive teaching, grant acquisition, and collaborative research background reflect both academic maturity and innovation. His professional journey exemplifies excellence, persistence, and a global perspective on healthcare research.

🔬 Research Focus:

Professor Hongliang Xin’s research centers on cellular biomimetic drug delivery systems and intelligent therapeutic strategies for brain diseases such as glioblastoma and ischemic stroke. His work integrates polymer chemistry, pharmacokinetics, and molecular targeting to design nanoparticles that can cross the blood-brain barrier with precision. A key innovation in his research is the use of Angiopep-conjugated polymers and ROS-responsive carriers to ensure site-specific and safe drug delivery. His dual-targeting PEG-PCL nanoparticle system has shown remarkable results in preclinical models of brain cancer, while his transcutaneous immunotherapy approach enhances anti-tumor immunity. Professor Xin’s focus also extends to thrombolytic delivery systems, neuroprotectants, and engineered nano-platelets for hematologic malignancies. With over a decade of focused work, his lab continues to address clinical challenges in oncology and neurology, aiming to translate nanoscale innovations into real-world therapeutics.

📚 Publications Top Notes:

  1. 🧠💊 Angiopep-conjugated PEG-PCL nanoparticles as dual-targeting system for brain glioma

  2. 🧬🛡 Anti-glioblastoma efficacy of paclitaxel-loaded Angiopep-conjugated PEG-PCL nanoparticles

  3. 💉🧫 Synergistic transcutaneous immunotherapy for checkpoint inhibitor delivery and tumor response

  4. 🧠🎯 2-deoxy-D-glucose functionalized PEG-PTMC nanoparticles for glioma targeting

  5. 🧠⚡ Boronic ester-dextran polymer nanoparticles responsive to ROS for stroke therapy

  6. 🧫🩸 Nano-platelets for enhanced treatment of multiple myeloma and thrombus

  7. 🧠🧬 Site-specific delivery of thrombolytics and neuroprotectants for ischemic stroke

  8. 🧠🧪 Brain targeting mechanism of Angiopep-conjugated PEG-PCL nanoparticles

  9. 🧠💉 Dual-targeted nanocarrier for treatment of brain ischemic stroke

  10. 💊🧠 Integrin-mediated PEG-PTMC nanoparticles for solid tumor penetration and paclitaxel delivery

🧾 Conclusion:

Professor Hongliang Xin is a highly qualified and impactful researcher whose contributions in intelligent, targeted drug delivery—especially for brain diseases—are both scientifically innovative and socially relevant. His work bridges critical gaps in nanomedicine and therapeutic targeting, and his publications are widely cited, reflecting broad recognition. With strategic focus on clinical translation and deeper global engagement, his already excellent profile could reach even greater heights.

Salvatore Chirumbolo | Cellular Stress Response | Innovative Research Award

Published on by Cell Biologist

Dr. Salvatore Chirumbolo | Cellular Stress Response | Innovative Research Award

Dr. Salvatore Chirumbolo, Università di Verona, Italy

Dr. Salvatore Chirumbolo is a distinguished Clinical Biochemist and Senior Researcher at the University of Verona, Department of Engineering for Innovation Medicine. He has made pioneering contributions in oxidative stress, immunopharmacology, systems biology, and ozone therapy. Author of over 400 scientific papers and several books, he is among Italy’s most cited biomedical scientists with an h-index of 46. His innovative work includes developing models for chaotic modulation in redox biology and proposing the concept of Shannon dissipation as a thermodynamic foundation for life. Dr. Chirumbolo has extensive editorial experience, serving on the boards of renowned journals including Scientific Reports, International Immunopharmacology, and Molecules. He actively collaborates with international institutions across Europe and promotes integrative, transdisciplinary biomedical approaches. His dedication to biophysical complexity and system-based innovation continues to influence translational medicine, making him an ideal nominee for the Research for Innovative Research Award.

Publication Profile:

Google Scholar

Scopus

✅ Strengths for the Award:

  1. Innovative Scientific Contributions:
    Dr. Chirumbolo’s concept of Shannon dissipation as the thermodynamic foundation of life represents a paradigm shift in theoretical biology. His model bridges information theory with biogenesis, advancing the frontiers of systems immunology and biological epistemology.

  2. Translational Research in Ozone Therapy:
    His chaotic modulation model for medical ozone effects introduces a systems-level interpretation of therapeutic mechanisms, with significant implications for redox biology, regenerative medicine, and inflammation management.

  3. Prolific Academic Output:
    With over 400 publications indexed in Scopus and Google Scholar, and an h-index of 46, Dr. Chirumbolo demonstrates sustained academic productivity, peer recognition, and impact in biomedical sciences.

  4. Editorial and Leadership Roles:
    He is actively involved with high-impact journals including Scientific Reports (Nature portfolio), International Immunopharmacology, and Molecules, contributing to global scientific discourse.

  5. Global Collaborations:
    His affiliations with institutions in Norway, Ukraine, Romania, Poland, and Italy reflect his commitment to cross-border scientific exchange and integrative research efforts.

🔧 Areas for Improvement:

  1. Patent and Industry Translation:
    Despite deep theoretical and experimental knowledge, Dr. Chirumbolo’s portfolio currently lacks patents or industrial consultancy projects. Advancing translational aspects of his models into commercial or clinical applications would enhance real-world impact.

  2. Public Communication and Outreach:
    While academically prolific, wider dissemination of his findings to non-specialist or policy-making audiences could increase societal relevance and interdisciplinary uptake.

🎓 Education:

Dr. Chirumbolo earned his Medical Specialization in Biochemical Chemistry in 1995, marking the beginning of his journey in biomedical sciences. His academic roots are grounded in clinical biochemistry, molecular biology, and translational medicine. He trained in Italy’s National Health System, where he directed various molecular biology laboratories, gaining firsthand experience in diagnostic innovation and experimental biochemistry. With a strong foundation in cellular and molecular biology, his educational path laid the groundwork for his systems-level understanding of biological complexity. His commitment to continuous learning is evident in his interdisciplinary research spanning immunology, redox biology, information theory, and ozone therapy. He is actively engaged in scientific discourse through editorial appointments and international conferences, nurturing the next generation of systems biologists and medical scientists. His academic lineage blends traditional biochemical education with pioneering insights into biological epistemology and complex systems science.

🧪 Experience:

Dr. Chirumbolo has over three decades of professional experience in biochemistry, molecular biology, and translational research. Starting in Italy’s National Health System, he directed molecular labs focusing on clinical diagnostics and immunological assays. He later transitioned to academia, becoming a Senior Researcher at the University of Verona. He has led major research initiatives involving oxidative stress, basophil biology, and the use of phytochemicals in chronic diseases. As an editor for journals like Scientific Reports, International Immunopharmacology, and Molecules, he has shaped international scientific dialogue. His collaborations span Italy, Norway, Ukraine, Romania, and Poland, involving diverse domains such as chemical biology and clinical immunology. He also contributes to bioinformatic modeling of redox systems and life origin theories. With over 400 indexed publications, Dr. Chirumbolo’s multidisciplinary expertise bridges clinical and theoretical biosciences, driving innovative solutions in modern medicine.

🔬 Research Focus:

Dr. Chirumbolo’s research focuses on biomedical systems, oxidative stress, and the thermodynamic foundations of life. He developed the novel concept of Shannon dissipation, linking informational entropy to the emergence of biological life, aligning with thinkers like Varela and Maturana. His work in ozone therapy led to the formulation of chaotic modulation models that explain its redox-based medical efficacy. He also investigates bioinformatic modeling, basophil signaling, phytochemical impacts, and nutraceutical interventions in chronic inflammation, allergy, and metabolic disorders. His models propose mechanistic insights into cell signaling and antioxidant networks, enhancing therapeutic targeting. Recent contributions include exploring the microvascular effects of SARS-CoV-2, the interface of redox dynamics and cellular adaptation, and ozone’s systemic regulatory properties. Through extensive collaborations, he integrates cellular, chemical, and systems-level research to push the boundaries of personalized and integrative medicine.

📚 Publications Top Notes:

  • 🧪 Ozone therapy addresses neuropathic pain in ulcerous wounds

  • 🍊 Something more about the role of flavonoids in aging

  • 🩸 Prolonged alterations in red blood cell rheology following mild SARS-CoV-2 infection: Implications for microvascular health

  • 💉 Intravenous glutathione should not be mismatched with ozone as an antioxidant therapy

  • 🌬️ Sonic transdermal transfer of ozone and its use in oxygen-ozone therapy. Wheat and chaff

  • 🧬 Effect of SARS-CoV2 S protein on red blood cells parameters. Some comments

  • ⚠️ Adverse effects following some practices of ozone therapy for disc herniation. Critical comments

  • 🧠 Post-infective myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and post-COVID as two puzzling faces of the same medal

  • 🦴 Synovial Fluid as a Crucial Component of the Joint Microenvironment in Rheumatoid Arthritis

  • ❤️ Aetiology and clinical manifestations of patients with non-dilated left ventricular cardiomyopathy. Some comments

🧾 Conclusion:

Dr. Salvatore Chirumbolo is highly suited for the Research for Innovative Research Award. His work exemplifies pioneering thought, multidisciplinary integration, and scientific originality. From foundational biological theory to clinically relevant applications like ozone therapy and oxidative stress modulation, his contributions address both the “why” and “how” of living systems. His influence is evident in his citation record, editorial appointments, and leadership in cutting-edge biomedical modeling.

 

Zhi Guo | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Prof. Dr Zhi Guo | Stem Cell Research | Best Researcher Award

Prof. Dr Zhi Guo | Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital | China

Dr. Zhi Guo is a distinguished expert in hematology with over 25 years of clinical and academic experience. Currently serving as Director, Academic Leader, Chief Physician, and Professor at the Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, he has been instrumental in advancing hematologic malignancy treatments in China. With extensive expertise in hematopoietic stem cell transplantation, Dr. Guo has successfully performed more than 1,300 transplant cases. He began his career at the PLA Army General Hospital, serving there for nearly two decades before transitioning to his current role. A prolific researcher, he has authored over 10 peer-reviewed publications and five books, contributing substantially to the understanding of CAR-T therapy, gut microbiota, and transplantation immunology. He is an active member of major national and international hematology associations and plays a vital role in formulating clinical consensus and guidelines in China.

publication profile:

Scopus

Strengths for the Award:

Dr. Zhi Guo exemplifies the qualities of an outstanding medical researcher and clinician. With nearly 25 years of clinical experience in hematology and over 20 years in hematopoietic stem cell transplantation, he stands out as a national leader in this field. His performance of more than 1,300 transplants, along with a strong academic footprint, including 10 SCI-indexed publications in 2024–2025, demonstrates both depth and innovation in his research. He has also contributed to national expert consensus and clinical guidelines, particularly in CAR-T therapy and intestinal microecology. Dr. Guo’s leadership roles across national academic committees and his active membership in the American Society of Hematology further highlight his international impact and collaborative influence.

Areas for Improvement:

While Dr. Guo’s achievements in clinical practice and research are significant, opportunities exist to increase global visibility by expanding his research collaborations internationally and publishing in higher-impact journals beyond regional scopes. Additionally, while five books have been authored, the addition of patents or translational innovations could enhance his profile in the realm of research commercialization and practical medical technologies.

Education :

Dr. Zhi Guo holds a strong academic background in clinical medicine and medical research. He earned his Bachelor’s degree in Medicine from Tongji Medical College in 2000. Subsequently, he pursued his postgraduate medical studies at the Third Military Medical University, completing it in 2007. His academic journey culminated with the attainment of a Doctor of Medicine (MD) degree from Wuhan University of Science and Technology. His education laid a strong foundation in hematology and clinical research methodologies. Each step in his educational path was marked by an emphasis on academic rigor and clinical competence, preparing him for a leadership role in medical science and hematologic research. His multidisciplinary background has enabled him to integrate clinical insights with advanced laboratory-based innovations, contributing to national-level guidelines and the development of cutting-edge CAR-T cell therapies and transplantation techniques.

Experience :

Dr. Zhi Guo brings nearly 25 years of clinical, academic, and leadership experience in the field of hematology. He began his professional journey at the PLA Army General Hospital, where he served from 2000 to 2018. During this period, he honed his clinical and procedural expertise in managing complex hematologic disorders. Since 2018, he has been leading the Department of Hematology at Huazhong University of Science and Technology Union Shenzhen Hospital as Director, Academic Leader, and Chief Physician. His rich experience includes more than 1,300 hematopoietic stem cell transplantations, encompassing autologous, allogeneic, and CAR-T integrated therapies. His leadership extends beyond clinical care, as he also mentors postgraduate medical students and leads multiple national and institutional research projects. Dr. Guo’s practical experience is balanced with his strategic contributions to medical consensus formulation and research-driven policy initiatives in cancer and immune-hematological disorders.

Research Focus :

Dr. Zhi Guo’s research centers on hematologic malignancies and hematopoietic stem cell transplantation, particularly the integration of cellular immunotherapy such as CAR-T cell treatments. His recent work includes pioneering anti-CD19, anti-CD7, and anti-BCMA CAR-T therapies for lymphomas and leukemias. Additionally, he has investigated the interplay between microbiota and immune modulation in transplantation, highlighting the role of gut and oral microbiomes in patient outcomes. His contributions have influenced the development of clinical guidelines for microbiota-related diagnostics and treatments in oncology. With more than 10 high-impact journal publications and ongoing projects in translational medicine, Dr. Guo’s work combines laboratory innovation with patient-centered applications. He has also authored expert consensus documents and national guidelines, helping shape China’s hematology and transplantation protocols. His commitment to interdisciplinary collaboration, clinical innovation, and translational research underscores his leading role in advancing modern hematology.

Publications Top Notes:

  1. 🧬 In vitro validation of anti-CD19 CAR-T cells with LSD1 shRNA for DLBCL – Front Immunol, 2025

  2. 🩸 Case of T-ALL treated with chemo + anti-CD7 CAR-T (retroviral vector) – Front Immunol, 2025

  3. 👶 Shaping oral/intestinal microbiota & immunity in first 1,000 days of life – Front Pediatr, 2025

  4. 💩 Fecal microbiota transplantation in acute GVHD treatment – J Cancer Res Ther, 2024

  5. 🔬 Chinese consensus on gut microecology lab standards – Exp Ther Med, 2024

  6. 🧪 2024 Chinese guidelines for intestinal microecology in cancer – J Cancer Res Ther, 2024

  7. 🧫 First MM case treated with ASCT + anti-BCMA CAR-T (retrovirus) – Heliyon, 2024

  8. 🧾 Rapid response in relapsed FL to anti-CD19 CAR-T with CMV – Int Immunopharmacol, 2024

  9. 🦷 Prognostic impact of oral microbiome in cancer survival – meta-analysis – Syst Rev, 2024

  10. 🧍‍⚕️ Expert consensus on gut microbiome & hematopoietic stem cell transplantation – Clin Transplant, 2024

Conclusion:

In conclusion, Dr. Zhi Guo is highly suitable for the Best Researcher Award. His combination of clinical excellence, academic leadership, and impactful research in hematology and stem cell transplantation positions him among the top contributors in this specialized field. With ongoing research in CAR-T cell therapies, microbiota influence on transplantation, and immuno-oncology, Dr. Guo continues to shape the future of hematologic cancer care. Recognizing his contributions with this award would be both fitting and encouraging for continued innovation in this vital area of medicine.

 

Fabian Fries | Gene Regulation Epigenetics | Young Scientist Award

Published on by Cell Biologist

Dr. Fabian Fries | Gene Regulation Epigenetics | Young Scientist Award

Dr. Fabian Fries , Universitätsklinikum des Saarlandes , Germany

Dr. Fabian N. Fries is a German ophthalmologist and senior consultant at Saarland University Medical Center. Born on July 18, 1990, in Germany, he has cultivated a career marked by clinical excellence, research productivity, and international experience. Following his medical studies at Saarland University, he gained practical experience across the U.S., Brazil, and Germany. Dr. Fries has authored over 15 peer-reviewed publications and earned an H-index of 16, reflecting his impactful contributions in ophthalmology. A polyglot and DAAD scholar, he is also actively engaged in professional societies like the German Ophthalmological Society. His research interests include corneal diseases, ocular surface disorders, and regenerative therapies involving limbal stem cells. Apart from his medical pursuits, he’s a competitive athlete, excelling in tennis and athletics. Dr. Fries combines clinical competence, research acumen, and a collaborative mindset, positioning him as an outstanding candidate for early-career research recognition.

Publication Profile:

Orcid

✅ Strengths:

  1. 📈 Strong Research Metrics

    • H-index: 16, i10-index: 22, and 742 citations—solid indicators of impactful and consistent academic output.

    • Authored 15 peer-reviewed publications in high-impact journals like The Ocular Surface, Experimental Eye Research, and International Journal of Molecular Sciences.

  2. 🧬 Innovative Research Focus

    • His work bridges molecular biology and clinical ophthalmology, especially in limbal stem cell deficiency, PAX6 gene regulation, miRNA expression, and corneal diseases.

    • Focus on translational science with direct implications for therapy and regenerative medicine.

  3. 🌍 International Exposure

    • Completed clinical internships in USA, Brazil, and Germany, showcasing adaptability, cultural competence, and international collaboration.

  4. 💼 Professional Leadership

    • Currently a Senior Consultant at Saarland University Medical Center.

    • Certified teaching assistant, actively mentoring young medical professionals.

  5. 🏅 Recognized Excellence & Extracurriculars

    • Multiple scholarships: DAAD, e-fellows.net, and Saarland University.

    • Athlete-scholar with national-level performance in tennis and athletics, highlighting discipline, commitment, and well-rounded personality.

  6. 🧠 Tech-Savvy & Multilingual

    • Proficient in SPSS, Java, SAP ERP, and fluent in 6 languages, positioning him uniquely for cross-disciplinary, global projects.

📉 Areas for Improvement:

  1. 🌐 Global Research Fellowships or Visiting Scientist Roles

    • While he has international clinical experience, postdoctoral research fellowships abroad (e.g., US, UK, or Japan) could further enrich his research perspective and expand collaborations.

  2. 📣 Greater Visibility as a Lead Investigator

    • Most of his studies are in collaboration with senior figures. More first-author or corresponding-author publications, and leading independent research grants, would bolster his profile.

  3. 🎤 Science Communication/Public Engagement

    • Active roles in public engagement, conferences, or science communication platforms would amplify his influence and visibility outside academic circles.

🎓 Education:

Dr. Fries completed his Abitur in Saarland, Germany in 2009 and subsequently pursued medicine at Saarland University, completing his state medical examination in 2016. His medical education was enriched by several international internships: Children’s of Alabama (USA), Instituto de Neurologia de Curitiba (Brazil), and various institutions in Germany. These experiences provided him with a strong foundation in global healthcare environments and interdisciplinary approaches to medical problems. His training emphasized ophthalmology, medical technology, and corneal research. In addition to his clinical education, he developed proficiency in research methodologies, statistical software (SPSS), and even programming in Java—an uncommon strength among clinicians. His multilingualism (German, English, French, Spanish, Portuguese, Latin) further reflects a well-rounded academic and professional profile. He has also received scholarships from the DAAD, Saarland University, and e-fellows.net. This robust educational background is a solid base for his continued clinical and academic excellence in ophthalmology.

💼 Professional Experience:

Dr. Fries is currently a Senior Consultant in Ophthalmology at Saarland University Medical Center (since 2021), where he also completed his residency (2016–2021). He brings over a decade of experience in clinical practice, teaching, and research. His clinical roles have spanned multiple specialties and continents, including stints at Children’s of Alabama, the Instituto de Neurologia de Curitiba, and top institutions in Germany. He has participated in pioneering electronic health record integration projects and led efforts in corneal transplant innovations. His experience also includes medical internships in both hospitals and private practices, providing a broad spectrum of exposure from surgical practice to patient-centered outpatient care. Additionally, he is a certified teaching assistant at Saarland University and has been actively involved in the supervision of junior residents and students. His commitment to high-standard care and continuous education is evident in his leadership roles and collaborative projects.

🏆 Awards and Honors:

Dr. Fries has received several academic and research accolades that highlight his potential as a leading young scientist. He was awarded scholarships from the prestigious DAAD (German Academic Exchange Service), Saarland University, and e-fellows.net, reflecting academic excellence and leadership. His athletic achievements include participation in the German University Tennis Championships (2015, 2016), where he won multiple regional titles and achieved a 5th place ranking in the German Team Athletics Championships (2014). In research, his contributions are recognized through a strong H-index of 16, 742 citations, and an i10-index of 22, underlining consistent and impactful scientific productivity. He is a member of key academic societies, including the German Ophthalmological Society, Professional Association of Ophthalmologists, and others since 2016. His well-rounded excellence in science, teaching, international exposure, and sports makes him an exceptional candidate for the Research for Young Scientist Award.

🔬 Research Focus:

Dr. Fabian Fries focuses his research on ocular surface diseases, particularly limbal stem cell deficiency, corneal dystrophies, and regenerative approaches in ophthalmology. His work dives deep into molecular mechanisms, such as PAX6 signaling, microRNA pathways, and retinoic acid signaling, all pivotal in corneal health and disease. Using advanced cell culture models and patient tissue analysis, his research offers insights into pathophysiological processes affecting corneal epithelial integrity. Additionally, he explores the impact of genetic mutations and inflammatory mediators on disease progression. Dr. Fries has contributed significantly to translational research, bringing lab discoveries into clinical settings, notably in corneal transplantation and novel therapeutic strategies. He also examines digital integration in ophthalmology via projects like FIDUS EHR implementation. His interdisciplinary, collaborative, and bench-to-bedside approach places him at the forefront of young clinician-scientists driving innovation in ophthalmology.

📚 Publications Top Notes:

  1. 🧬 Effect of MiRNA 204-5P Mimics and LPS on Retinoic Acid Signaling in Limbal Epithelial Cells

  2. 🔬 Decreased PAX6 and DSG1 in Corneal Epithelium of EBMD, SND, and Pterygium Patients

  3. 🧫 FABP5 and DSG1 Downregulation after PAX6 Knockdown in Limbal Cells

  4. 💻 Employee Survey Post-FIDUS EHR Introduction at Saarland Eye Hospital

  5. 👁 Endothelial Cell Density and Corneal Thickness Post-Keratoplasty for Acanthamoeba Keratitis

  6. 🩸 Intravenous Fibrinolysis for Nonarteritic Central Retinal Artery Occlusion – Feasibility Study

  7. ⚠️ Pronounced Band Keratopathy in Refsum’s Syndrome – Case Report

  8. 🔎 Unilateral Macular Pigment Epitheliitis in a 38-Year-Old – Diagnostic Insights

  9. 🧬 MicroRNA and Gene Expression Changes in Limbal Deficiency Modulated by PAX6 Mutation

  10. 🧠 Acute Visual Loss from Basilar Artery Aneurysm-induced Subarachnoid Hemorrhage

🏁 Conclusion:

Dr. Fabian N. Fries stands out as a highly qualified, ambitious, and impactful early-career scientist whose research bridges the gap between basic science and clinical innovation in ophthalmology. His contributions to ocular surface research, particularly in the context of limbal stem cells and gene regulation, are of significant academic and therapeutic value. He brings a unique mix of clinical excellence, internationalism, technological proficiency, and scientific curiosity.

Xin Li | Biomaterials | Best Researcher Award

Published on by Cell Biologist

Dr. Xin Li | Biomaterials | Best Researcher Award

Dr. Xin Li , The Chinese University of Hong Kong , Hong Kong

Dr. Xin Li is a dynamic and prolific researcher in the field of biomedical polymer materials and nanomedicine. With a Ph.D. from RWTH Aachen University under the mentorship of Prof. Andrij Pich, Dr. Li has carved a niche in responsive nanogels, ultrasound-triggered drug delivery, and smart biosensors. He currently holds a position as a Research Associate at The Chinese University of Hong Kong, following a postdoctoral fellowship at HKUST. Dr. Li has published over 70 SCI-indexed papers, earned 2600+ citations, holds 10 patents, and contributed to one academic book. His research stands out in top-tier journals like Nature Communications, Chem, Matter, and Advanced Materials. Recognized globally, he has led several high-impact research projects and received prestigious honors such as the 2024 JPA Prize and the 2021 Young Scientist Award. Dr. Li’s innovative mindset and cross-disciplinary expertise continue to push boundaries in biomedical engineering.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Outstanding Publication Record 📚
    Dr. Li has authored over 70 SCI-indexed publications in top-tier journals such as Nature Communications, Chem, Matter, Advanced Materials, and Angewandte Chemie. With an H-index of 32 and 2600+ citations, he demonstrates a strong impact in his field.

  2. Innovative and Translational Research 💡
    His work focuses on stimuli-responsive nanogels, mechanophore-based drug delivery, and biosensors, directly addressing real-world medical challenges like cancer therapy and infection monitoring.

  3. Leadership in International Projects 🌏
    Dr. Li has served as Principal Investigator and Co-leader of prestigious funding programs, including the Shanghai Overseas High-level Young Talent Program, Pujiang Program, and a Sino-German Research Grant, totaling over ¥1 million and €257,000.

  4. Interdisciplinary Expertise 🔬
    With a background in polymeric materials, biomedical engineering, and biophysics, he bridges the gap between material science and clinical applications, pushing the boundaries of modern nanomedicine.

  5. Recognized Honors and Editorial Roles 🏆
    Awards like the 2024 JPA Prize and the 2021 Young Scientist Award, along with his editorial contributions, highlight both his recognition and thought leadership in the scientific community.

⚠️ Areas for Improvement:

  1. Broader Industry Collaboration
    While Dr. Li has a strong academic and funding track record, increasing collaboration with biotech or pharmaceutical industries could further enhance the translational value of his research.

  2. Public Engagement and Science Communication
    As his work involves complex and novel biomedical technologies, more active engagement in science communication or public-facing platforms could broaden the reach and societal impact of his innovations.

  3. Diversified International Experience
    Though already globally active (Germany, China, Hong Kong), involvement in North American or broader EU collaborative networks might further strengthen his research diversity and global visibility.

🎓 Education:

Dr. Xin Li holds a Ph.D. in Biomedical Polymer Materials from RWTH Aachen University, Germany (2018–2023), where he worked under Prof. Andrij Pich, focusing on functional nanogels and stimuli-responsive systems for precise therapy. Prior to this, he earned an M.S. in Biomedical Engineering from Donghua University (2014–2017), supervised by Prof. Xiangyang Shi, with work centered around nanomaterials for gene and drug delivery. His academic journey began with a B.E. in Polymeric Materials and Engineering from Zhejiang A & F University (2010–2014), mentored by Prof. Pingan Song and Prof. Liang Chen. Across each academic stage, Dr. Li demonstrated an impressive aptitude for interdisciplinary innovation, combining materials science, chemical engineering, and biomedical applications. His strong educational foundation set the stage for his successful research career in developing next-generation nanomedicines and imaging technologies.

💼 Experience:

Dr. Xin Li currently serves as a Research Associate at The Chinese University of Hong Kong (2024–present), advancing cutting-edge research in nanomedicine. Prior to this, he was a Postdoctoral Fellow at The Hong Kong University of Science and Technology (2023–2024), where he expanded his expertise in responsive nanomaterials. His earlier research assistant roles at the DWI-Leibniz Institute (2022–2023) and Donghua University (2017) enriched his multidisciplinary experience. During his doctoral training at RWTH Aachen, Dr. Li led multiple collaborations and mentored students, reflecting his leadership potential. He has independently secured and led major grants like the Shanghai Overseas High-level Young Talent Program and the Pujiang Program. Dr. Li’s professional trajectory demonstrates a steady rise marked by impactful research, international collaboration, and continuous innovation in materials for imaging, therapy, and diagnostics.

🏅 Awards and Honors:

Dr. Xin Li has been consistently recognized for his contributions to biomedical engineering and nanomedicine. In 2024, he received the JPA Prize for his role as an Excellent Young Editorial Board Member. Earlier, in 2021, he was honored with the Young Scientist Award at the 3rd Global Experts Meeting on Chemistry and Medicinal Chemistry, acknowledging his innovative research in responsive drug delivery systems. He also earned the CSC-RWTH Scholarship in 2017, awarded by the China Scholarship Council for his doctoral studies in Germany, reflecting academic excellence and international research promise. In addition to these accolades, he has been entrusted with leadership roles in competitive grant programs such as the Shanghai Overseas High-level Talent Plan and the Sino-German Center collaborative research grant. These honors highlight Dr. Li’s status as an emerging leader in translational nanomedicine and interdisciplinary biomedical research.

🔬 Research Focus:

Dr. Xin Li’s research focuses on the design and development of stimuli-responsive nanogels, ultrasound-activated drug delivery systems, and smart biosensors. He is particularly interested in leveraging physical triggers (e.g., ultrasound, radiotherapy) to enable precise drug activation, offering high specificity and minimal side effects. His work on polymer mechanochemistry and hydrogel-based biosensors has opened new frontiers in non-invasive cancer therapy, infection monitoring, and imaging. With a deep understanding of polymer physics, biomedical engineering, and nanotechnology, Dr. Li integrates multiple disciplines to tackle challenges in tumor-targeted delivery, photothermal therapy, and metabolic reprogramming. His future focus includes developing clinically translatable systems for real-time therapy monitoring, immune modulation, and personalized medicine. By combining fundamental research with practical applications, Dr. Li aims to revolutionize how diseases like cancer and infections are diagnosed and treated.

📚 Publications Top Notes:

  1. 🧬 Transvascular transport of nanocarriers for tumor delivery, Nat. Commun., 2024

  2. 🧠 Leukocyte-nanomedicine system for targeted delivery and precise theragnostics, Chem, 2022

  3. 🩹 A wireless and battery-free DNA hydrogel biosensor for wound infection monitoring, Matter, 2022

  4. 💊 Radiotherapy-triggered prodrug activation: A new era in precise chemotherapy, Med, 2022

  5. 🧪 Engineered living hydrogels for robust biocatalysis in pure organic solvents, Cell Rep. Phys. Sci., 2022

  6. ☢️ Radiotherapy activated systems for precise tumor treatment, Nat. Rev. Cancer, 2025

  7. 💧 Sprayed aqueous microdroplets for spontaneous synthesis of functional microgels, Angew. Chem. Int. Ed., 2025

  8. 🧬 Functional dendrimer nanogels for DNA delivery and gene therapy of tumors, Angew. Chem. Int. Ed., 2025

  9. 🔥 Global cold local photothermal-mediated synergistic metabolic antitumor immunity, Adv. Mater., 2025

  10. 📡 Network topology of nanogels regulates mechanophore activation for ultrasound-mediated therapy, Angew. Chem. Int. Ed., 2025

🧾 Conclusion:

Dr. Xin Li is highly suitable and deserving of the Best Researcher Award. His exceptional research output, innovative project leadership, and contributions to translational biomedical science place him among the leading young researchers globally. While there is room for expanding industry ties and global engagement, his trajectory, impact, and recognition already demonstrate excellence well above typical benchmarks. Dr. Li exemplifies the future of interdisciplinary research and is a valuable asset to the global scientific community.